Ascendis Pharma A/S’s (ASND) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $170.00 price target on the biotechnology company’s stock.

Several other analysts have also weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Stifel Nicolaus upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday. StockNews.com downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. dropped their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Finally, The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

ASND stock opened at $126.51 on Friday. The company’s fifty day simple moving average is $132.30 and its 200 day simple moving average is $132.60. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the company. Signaturefd LLC lifted its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. increased its stake in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the last quarter. Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $217,000. Searle & CO. purchased a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth approximately $205,000. Finally, Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.